dc.creator | Stamatis P., Turkiewicz A., Englund M., Turesson C., Mohammad A.J. | en |
dc.date.accessioned | 2023-01-31T10:02:05Z | |
dc.date.available | 2023-01-31T10:02:05Z | |
dc.date.issued | 2022 | |
dc.identifier | 10.1093/rheumatology/keab269 | |
dc.identifier.issn | 14620324 | |
dc.identifier.uri | http://hdl.handle.net/11615/79373 | |
dc.description.abstract | Objective: To characterize the epidemiology of temporal artery biopsy-positive (TAB+) GCA, including trends in incidence, seasonal variation and prevalence in Skåne, the southernmost region of Sweden. Methods: All histopathology reports of TABs from 1997 through 2019 were reviewed to identify patients diagnosed with TAB+ GCA. Incidence rates based on the 23-year period and the point-prevalence at 31 December 2014 were determined. An alternative prevalence calculation included only TAB+ GCA patients living in the study area and receiving immunosuppressant therapy on the point-prevalence date. Results: One thousand three hundred and sixty patients were diagnosed with TAB+ GCA (71% female). The average annual incidence 1997-2019 was 13.3 (95% CI: 12.6, 14.0) per 100 000 inhabitants aged ≥50 years and was higher in females (17.8; 95% CI: 16.7, 18.9) than in males (8.2; 95% CI: 7.4, 9.0). The age- and sex-standardized incidence declined from 17.3 in 1997 to 8.7 in 2019, with incidence ratio (IR) of 0.98 per year (95% CI: 0.98, 0.99). A seasonal variation was observed with higher incidence during spring than winter [IR = 1.19 (95% CI: 1.03, 1.39)]. The overall point-prevalence of TAB+ GCA was 127.1/100 000 (95% CI: 117, 137.3) and was 75.5 (95% CI: 67.7, 83.3) when including only patients receiving immunosuppressants. Conclusion: Over the past 2 decades, the incidence of biopsy-confirmed GCA has decreased by ∼2% per year. Still, a high prevalence of GCA on current treatment was observed. More cases are diagnosed during spring and summer than in the winter. © 2021 The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. | en |
dc.language.iso | en | en |
dc.source | Rheumatology (United Kingdom) | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85125013713&doi=10.1093%2frheumatology%2fkeab269&partnerID=40&md5=b7730f3682b4279bf67e5516eaac3fd7 | |
dc.subject | disease modifying antirheumatic drug | en |
dc.subject | glucocorticoid | en |
dc.subject | immunosuppressive agent | en |
dc.subject | adult | en |
dc.subject | aged | en |
dc.subject | Article | en |
dc.subject | biopsy | en |
dc.subject | blood vessel biopsy | en |
dc.subject | controlled study | en |
dc.subject | female | en |
dc.subject | giant cell arteritis | en |
dc.subject | histopathology | en |
dc.subject | human | en |
dc.subject | human tissue | en |
dc.subject | immunosuppressive treatment | en |
dc.subject | incidence | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | point prevalence | en |
dc.subject | prevalence | en |
dc.subject | seasonal variation | en |
dc.subject | spring | en |
dc.subject | Sweden | en |
dc.subject | winter | en |
dc.subject | biopsy | en |
dc.subject | giant cell arteritis | en |
dc.subject | middle aged | en |
dc.subject | Sweden | en |
dc.subject | Aged | en |
dc.subject | Biopsy | en |
dc.subject | Female | en |
dc.subject | Giant Cell Arteritis | en |
dc.subject | Humans | en |
dc.subject | Incidence | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Prevalence | en |
dc.subject | Sweden | en |
dc.subject | Oxford University Press | en |
dc.title | Epidemiology of biopsy-confirmed giant cell arteritis in southern Sweden - an update on incidence and first prevalence estimate | en |
dc.type | journalArticle | en |